Emerging research suggest Retatrutide , a dual activator targeting both incretin and GIP , may represent a promising development for body management . Early clinical tests have shown impressive decreases in visceral mass , conceivably exceeding existing body composition treatments. Nevertheless , further evaluation is needed to fully determine its